Brooks Hill Partners has added Astrocyte Pharmaceuticals to their portfolio. This drug development company is dedicated to using the neuroprotective benefits of selective astrocyte activation to create novel therapies for brain injury patients.
Learn more about Astrocyte here.
Brooks Hill Partners is a life sciences consultancy and early-stage health tech venture capital firm that partners with passionate companies across the biopharma and healthcare landscape. Please contact us to learn more about how we can help you today. For more information, visit https://www.brookshillpartners.com/ and follow us on LinkedIn.